XESM
UPR
Market cap1.41bUSD
Jun 18, Last price
4.75EUR
1D
0.21%
1Q
23.70%
IPO
305.98%
Name
Uniphar PLC
Chart & Performance
P/E
19.20
P/S
0.45
EPS
0.25
Div Yield, %
0.38%
Shrs. gr., 5y
8.27%
Rev. gr., 5y
10.72%
Revenues
2.77b
+8.51%
Net income
64m
+43.26%
CFO
124m
+136.65%
Dividend
Sep 11, 20250.0071 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Uniphar plc functions as a multifaceted healthcare solutions provider, serving markets across the Republic of Ireland, the United Kingdom, and various international territories. Its operations are segmented into three primary divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail. The Commercial & Clinical division provides outsourced services encompassing sales, marketing, and integrated account management for pharmaceutical and medical device manufacturers, also managing the distribution and support for medical device producers. The Product Access division facilitates access to pharmaceutical and medical treatments through on-demand services, fostering vital connections between manufacturers and healthcare stakeholders; additionally, its exclusive access services establish tailored distribution agreements for crucial pharmaceutical brands. The Supply Chain & Retail division manages the pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary practices, and also oversees a network of retail pharmacies operating under the Life, Allcare, and Hickey's banners. Beyond its core divisional activities, Uniphar delivers a broad spectrum of specialized services, including pharmacy support, comprehensive pharmaceutical supply chain management, specialist nursing and infusion services, medical device distribution, and healthcare technology solutions. It further extends its expertise through data intelligence, consultancy, pharmaceutical advisory, and medical affairs services, alongside online pharmacy operations, product fostering, and data analytics for the pharmaceutical sector. Established in 1967, Uniphar plc maintains its headquarters in Dublin, Ireland.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||